

9-1-2016

Systemic inflammatory response syndrome (SIRS) after extracorporeal membrane oxygenation (ECMO): Incidence, risks and survivals.

Karthik Thangappan

Thomas Jefferson University, karthik.thangappan@jefferson.edu

Nicholas C. Cavarocchi

Thomas Jefferson University, nicholas.cavarocchi@jefferson.edu

Michael Baram

Thomas Jefferson University, Michael.Baram@jefferson.edu

Brandi Thoma

Thomas Jefferson University, brandi.thoma@jefferson.edu

Hitoshi Hirose

Thomas Jefferson University, Hitoshi.Hirose@Jefferson.edu

[Let us know how access to this document benefits you](#)

Follow this and additional works at: <http://jdc.jefferson.edu/surgeryfp>Part of the [Pulmonology Commons](#), and the [Surgery Commons](#)

Recommended Citation

Thangappan, Karthik; Cavarocchi, Nicholas C.; Baram, Michael; Thoma, Brandi; and Hirose, Hitoshi, "Systemic inflammatory response syndrome (SIRS) after extracorporeal membrane oxygenation (ECMO): Incidence, risks and survivals." (2016). *Department of Surgery Faculty Papers*. Paper 144.

<http://jdc.jefferson.edu/surgeryfp/144>

**Systemic Inflammatory Response Syndrome (SIRS) after Extracorporeal Membrane
Oxygenation (ECMO): Incidence, Risks and Survivals.**

None of the authors has a conflict of interest regarding this paper.

Word Count: 2411

Abstract

Introduction: Systemic inflammatory response syndrome (SIRS) is frequently observed after extracorporeal membrane oxygenation (ECMO) decannulation; however, these issues have not been investigated well in the past.

Methods: Retrospective chart review was performed to identify post-ECMO SIRS phenomenon, defined by exhibiting 2/3 of the following criteria: fever, leukocytosis, and escalation of vasopressors. The patients were divided into 2 groups: patients with documented infections (Group I) and patients with true SIRS (Group TS) without any evidence of infection. Survival and pre-, intra- and post- ECMO risk factors were analyzed.

Results: Among 62 ECMO survivors, 37 (60%) patients developed the post-ECMO SIRS phenomenon, including Group I (n= 22) and Group TS (n=15). The 30-day survival rate of Group I and TS was 77% and 100%, respectively ($p=0.047$), although pre-decannulation risk factors were identical.

Conclusions: SIRS phenomenon after ECMO decannulation commonly occurs. Differentiating between the similar clinical presentations of SIRS and infection is important and will impact clinical outcomes.

Key words: ECMO; SIRS; infection.

List of Abbreviations

APACHE: acute physiology and chronic health evaluation.

ECMO: extracorporeal membrane oxygenation.

E-CPR: extracorporeal membrane oxygenation assisted cardiopulmonary resuscitation.

MELD: model for end-stage liver disease.

SAPS: simplified acute physiology score.

SIRS: systemic inflammatory response syndrome.

WBC: white blood cell.

Introduction

Extracorporeal membrane oxygenation (ECMO) support is well-established technology that provides both circulatory and respiratory support in patients with severe refractory cardiopulmonary failure.¹ ECMO stabilizes hemodynamics quickly in patients with severe hemodynamic and respiratory instability. While hemodynamics are restored and stabilized by ECMO, end-organ function is allowed to recover.² Patients on ECMO are decannulated once organ recovery criteria are met. If cardiac recovery has not occurred, the patient can be assessed for implantable mechanical support.

Systemic inflammatory response syndrome (SIRS), including fever, leukocytosis, and vasodilation is often observed during ECMO and related to either the ECMO circuit and/or the patient disease processes.³ This SIRS phenomenon during ECMO generally resolves as the primary disease is treated; the SIRS phenomenon should always be absent at the time of decannulation. However, we have often encountered the SIRS phenomenon after ECMO decannulation. The long-standing cannula and extracorporeal circuit kept for a period of time during ECMO may be responsible for blood stream infections.⁴ Similarly, long-term ventilator support may increase the chance of ventilator associated pneumonia and subsequent development of sepsis.⁴ Additionally, surgical interventions required for repair of the vessel after decannulation may complicate the postoperative course. Understanding the nature of the post-decannulation SIRS phenomenon and differentiating the similar clinical presentations of SIRS from sepsis could be important for clinicians who manage ECMO patients, since this can affect patient outcomes. Although we frequently observe these SIRS phenomena after ECMO decannulation, to our knowledge, no research about this issue has been undertaken. Thus, we performed this retrospective study in order to 1) identify the incidence of post-decannulation SIRS, 2) find the incidence of infection, 3) investigate the possibility of differentiating SIRS from infection, and 4) study the outcome of patients based on the presence of SIRS or infection.

Methods

Between July 2010 and June 2014, 122 ECMO procedures via peripheral cannulation were performed at our institution.^{4,5} Medical records of patients who survived ECMO were reviewed, and

their pre-, intra-, and post-ECMO data were entered into a structured database after approval from the institutional review board. Patients who died within 48 hours of ECMO decannulation were excluded from the study.

Veno-arterial ECMO from femoral cannulation was used for patients with cardiac failure.⁴ Patients with respiratory failure underwent veno-venous ECMO via single right internal jugular cannulation,⁵ although a minority of these patients underwent veno-arterial ECMO due to anatomy, severe hypotension, ventricular failure, or technical reasons. ECMO circuits included a Rotaflow centrifugal pump (Maquet, Rastatt, Germany) and a Quadrox-D diffusion membrane hollow-fiber oxygenator (Maquet, Rastatt, Germany). All patients were afebrile without evidence of on-going active infection or SIRS at the time of decannulation, per our institutional practice guidelines. ECMO decannulation was performed in the operating room with direct vessel repair.^{4,5} Peri-operative antibiotics were used for only 24 hours post-decannulation unless a course of antibiotics initiated during ECMO were being completed. Antibiotics were extended past 24 hours post-decannulation based on clinical judgment if a patient exhibited signs of a new infection.

Post-ECMO decannulation “SIRS phenomenon” was defined as having 2 out of the 3 of the following criteria after ECMO decannulation regardless of the presence of infection: fever (temperature > 101.5 °F), leukocytosis (white blood cell [WBC] >12,000, or 25% increase from pre-decannulation baseline), and escalation of vasopressors compared to the patient’s pre-decannulation baseline. Other diagnostic criteria of the SIRS, such as increase in heart rate or respiratory rate were not used for this study since these may be artificially modified due to the use of inotropes, degree of sedation, and ventilator settings. The patients who were found to have the SIRS phenomenon were further divided into 2 groups: SIRS phenomenon with evidence of infection (Group I) and true SIRS without evidence of infection (Group TS). Evidence of infection included positive blood, sputum, wound, or stool cultures. The presence of the infection was divided into “carried over” which was defined as infection present at the time of cannulation or during ECMO, but controlled appropriately at the time of the decannulation,

and “new infection after ECMO decannulation” which was defined as culture positive infection diagnosed after ECMO decannulation. Figure 1 illustrates the division of patient groups used in the study.

Risk factors including patient demographics, pre-ECMO, intra-ECMO, and post-ECMO parameters were retrospectively analyzed to identify risk factors of developing the post-decannulation SIRS phenomenon and variables that can differentiate between post-decannulation infection and true SIRS. Categorical variables and continuous variables were compared between the two groups using Chi-Square analysis (Fisher tests if small sample size) or two-tailed t-test, as appropriate. A p-value of less than 0.05 was considered to be significant.

Results

A total of 62 patients who survived ECMO were identified during the study period. Among them, 37 (60%) patients developed the SIRS phenomenon based on the criteria. Table 1 compared the demographics of the patients with post-decannulation SIRS phenomenon vs. no SIRS phenomenon. There were no significant differences in pre-ECMO risk factors, hematology, or chemistry values except for following: pre-ECMO lactate (4.8 ± 4.6 mmol/L for the patients with SIRS phenomenon vs. 2.9 ± 2.4 mmol/L without SIRS phenomenon, $p=0.038$) and alanine aminotransferase (93 ± 190 IU/L vs. 288 ± 440 IU/L, $p=0.041$). Pre-decannulation demographics, pre-decannulation laboratory data, and length of ECMO were similar between those who developed post-decannulation SIRS phenomenon and those who did not. Similarly, complications during ECMO and transfusions during ECMO (15 ± 20 units packed blood cell transfusion for those with SIRS phenomenon vs. 16 ± 18 units for those without SIRS phenomenon) were not significantly different. The 30-day survival after ECMO decannulation was not different between with and without post-decannulation SIRS phenomenon (86% with the SIRS phenomenon vs. 76% without the SIRS phenomenon, $p=0.289$).

Among those who had post-decannulation SIRS phenomenon, 22 patients (59% among SIRS phenomenon patients, 35% among all studied patients) had evidence of infection (Group I): bacteremia in 7 (32%), pneumonia in 12 (56%), surgical site infection in 3 (14%), and *Clostridium difficile* infection in 1 (4.5%), with 5 patients having overlapping infections. Out of these 22 patients, 9 patients (41%) had

carried over an infection that developed either at the time of ECMO cannulation or during ECMO, although these infections had been controlled with appropriate antibiotics. The remaining 13 patients (59%) had infections that developed after decannulation. In Group TS, which included 15 patients (41% among SIRS phenomenon patients, 24% among all studied patients), no evidence of infection was found despite aggressive investigation of possible sources of infection including serial cultures and imaging tests. Demographics of Group I and Group TS are shown in Table 2. Risk factor analysis showed that metabolic acidosis at the time of ECMO cannulation was less frequently observed in Group I than in Group TS (Group I vs. Group TS: pH 7.32 ± 0.12 vs. pH 7.23 ± 0.11 , $p=0.031$; and HCO_3^- 23 ± 6 mmol/L vs. HCO_3^- 19 ± 5 mmol/L, $p=0.038$ respectively). Pre-ECMO demographics, pre-ECMO laboratory data, length of ECMO, pre-decannulation laboratory data, complications during ECMO, and transfusions during ECMO were not different between Group I and Group TS.

Individual components of the SIRS phenomenon after decannulation of ECMO are shown in Table 3. Development of fever (initial day of fever, length of fever), leukocytosis (initial day of leukocytosis, duration of leukocytosis), and vasopressor usage (number of patients requiring vasopressor escalation, duration of vasopressor use) were similar between Group I and Group TS. In comparing variables of SIRS phenomenon between the two groups, the only difference found was the peak WBC count (Group I vs. Group TS: 30.1 ± 13.3 B/L vs. 21.3 ± 7.7 B/L, $p=0.04$). Peak WBC counts above 30,000 were more often found in Group I (46%) than in Group TS (14%), $p=0.026$. Regardless of the presence of infection or not, the usage of antibiotics beyond the 24-hour prophylaxis in patients who had post-decannulation SIRS phenomenon was similar between Group I and Group TS (antibiotics usage 68%, length of use 8.7 ± 6.1 days in Group I vs. antibiotics usage 53%, length of use 6.5 ± 4.9 days in Group TS).

A small number of the patients had procalcitonin levels measured after ECMO decannulation due to clinical suspicion of infection (22 patients in Group I and 8 patients in Group TS). The mean procalcitonin was 3.3 ± 1.8 ng/dl in Group I and 1.8 ± 1.7 ng/dl in Group TS, $p=0.2552$. The trend of higher procalcitonin values was observed more in Group I than in Group TS.

The post-decannulation 30-day survival rate was lower in Group I (77%, 17/22) than in Group TS (100%, 15/15) with $p=0.047$. Of the five patients in Group I who died within 30 days, three of those deaths were related to post-decannulation infection (two due to infection related to permanent left ventricular assist device implantation and subsequent open chest management unrelated to ECMO, one due to severe pneumonia which developed after ECMO decannulation), and the other two were related to cardiac arrest secondary to possible in-stent thrombosis after ECMO removal. The survival of those who had post-decannulation infection carrying over from ECMO was 78% (7/9), which was similar to that of those who developed new infections after ECMO removal (77%, 10/13).

Based on the SIRS phenomenon criteria, there were 25 patients who did not have the SIRS phenomenon. Among these patients without SIRS phenomenon, 10 patients (40%) had evidence of infection and 15 patients (60%) had no evidence of infection. The survival rates were 60% and 87%, respectively ($p=0.126$).

Discussion

This study showed a frequent incidence of the SIRS phenomenon including fever, elevation of WBC, and hypotension requiring vasopressors after decannulation of ECMO, even though none of these patients have the SIRS phenomenon before decannulation of ECMO. Almost all patients developed one of the three criteria of the post-decannulation SIRS phenomenon, and two-thirds of the patients fell under our definition of the SIRS phenomenon. Although risk factor analyses showed pre-ECMO high lactate and low alanine aminotransferase were associated with development of the SIRS phenomenon after ECMO decannulation, we believe this pre-ECMO metabolic disarrangement most likely does not contribute an essential role to the development of the SIRS phenomenon since these levels were normalized before decannulation (Table 1). Thus, the risk factors for development of the post-decannulation SIRS phenomenon remain undetermined.

Among those who had the SIRS phenomenon, the patterns of fever, leukocytosis and vasopressor requirements were almost identical between those who had infection and those who did not, although the outcomes were significantly inferior in the patients who had infections compared to those who had true

SIRS. Once patients developed the SIRS phenomenon after ECMO decannulation, it could continue for almost a week regardless of the presence of infection. However, a survival difference was clear based on the presence of infection. The only difference in the SIRS phenomenon criteria between Group I and TS was the highest WBC count. Patients with infection developed higher WBC counts; although patients with true SIRS also had elevated WBC count. Although leukocytosis is not specific to infection, a WBC count greater than 30,000 is more likely infectious in etiology. Extensive work up is necessary in these patients, and empiric antibiotics are recommended.

The high incidence of the post-ECMO decannulation SIRS phenomenon is unique and has not previously been noted in the literature. Although Aubron et al. demonstrated that bleeding is a frequent complication of ECMO,⁶ our study showed that neither bleeding events or transfusion requirement did not significantly impact the development of SIRS or infections after ECMO decannulation.

Peri-operative antibiotics were used for 24 hours after ECMO decannulation, unless the patient had ongoing treatment for infection during or prior to the ECMO period. Identifying the infection shortly after ECMO decannulation may be challenging. Our study showed that among those who had the SIRS phenomenon, more than half (~ 60%) of the patients had a significant infection, which affected the 30-day survival. Patients with the SIRS phenomenon with a suspected infection should be treated aggressively with broad-spectrum antibiotics until culture results are available. Due to lack of clear clinical differentiation between infection and the SIRS phenomenon, empiric antibiotics were often employed in these patients. This may potentially increase costs and antimicrobial resistance; however, we did not analyze these variables.

Although infection is a risk factor for post-decannulation death, it may be difficult to identify infections since finalized culture results may take up to 5 days. Since 2012, we have used the procalcitonin level as a part of the work up for infection in conjunction with routine cultures.⁷ Procalcitonin is a biomarker of infection and has been reported to be more specific than WBC count or C-reactive protein. Based on our previous study,⁷ the procalcitonin level used to identify infection was 2 ng/dl.⁷ Among patients who had a procalcitonin level measured after ECMO decannulation, we found a

trend of higher procalcitonin values in Group I than in Group TS, although the sample size was too small to conclude statistical significance. Since the procalcitonin value can be obtained as a point of care assay within hours of collection of the sample, procalcitonin may have a role in the early prediction of infection in patients with SIRS phenomenon after decannulation of ECMO.

This study has limitations due to a small sample size, single institution practice, and retrospective nature. Identification of infection was also a limitation. We defined infection as the presence of positive culture results; however, the culture results may be dependent on the use of antibiotics. The use of antibiotics in patients with the SIRS phenomenon was determined by the clinical judgment of a multi-disciplinary intensive care team with infectious disease consultation. Since post-decannulation infection increased the mortality in this study, routine prolonged courses of broad-spectrum antibiotics could be considered to minimize the risk of the post-decannulation infection, although this incidence of surgical site infection in this study was minimal. Future multi-centered studies with larger patient populations would be necessary to further investigate this post-ECMO SIRS phenomenon, along with standardizing decannulation techniques, assessment of infection, and antimicrobial management strategies.

Conclusions

Both post-ECMO SIRS phenomenon (~60%) and post-decannulation infection (~60% including infection carried over during ECMO, and ~35% newly developed infection after ECMO decannulation) were common in our single institution experience. The differentiation of infection from true SIRS was difficult and remains challenging. The outcomes of those who had infection after ECMO decannulation were poor, while 100% of true SIRS patients survived. The SIRS phenomenon after ECMO decannulation should be treated as infection until proven otherwise in order to optimize hospital outcomes.

Table 1: Demographics of patients with and without SIRS phenomenon. Data are expressed as number (%) or mean \pm standard deviation.

	SIRS Phenomenon n=37	No SIRS Phenomenon n=25	p-value
Pre-ECMO Demographics			
Age (years)	48 \pm 13	47 \pm 15	0.787
Male gender	29 (78%)	15 (60%)	0.118
Cardiac ECMO	24 (65%)	12 (48%)	0.187
Respiratory ECMO	13 (35%)	13 (52%)	0.187
E-CPR	5 (14%)	5 (20%)	0.496
Clinical diagnoses			
Cardiogenic Shock	25 (68%)	12 (48%)	0.123
Post-cardiotomy failure	5 (14%)	1 (4.0%)	0.214
Acute respiratory distress syndrome	10 (27%)	10 (40%)	0.284
Pre-ECMO laboratory data			
White blood cell count (B/L)	13.1 \pm 6.9	14.3 \pm 7.7	0.533
Creatinine (mg/dl)	1.5 \pm 0.9	1.4 \pm 0.8	0.648
Bilirubin (mg/dl)	1.4 \pm 1.6	1.3 \pm 1.2	0.780
Aspartate aminotransferase (IU/L)	160 \pm 190	290 \pm 419	0.151
Alanine aminotransferase (IU/L)	93 \pm 190	288 \pm 440	0.041
Lactate (mmol/L)	4.8 \pm 4.6	2.9 \pm 2.4	0.038
Pre-ECMO Scores			
SAPS II	53.6 \pm 15.1	56.5 \pm 19.6	0.534
APACHE II	28.2 \pm 8.3	27.8 \pm 7.3	0.842
MELD	15.6 \pm 7.6	13.7 \pm 6.2	0.285
Complication during ECMO			
Stroke	2 (5%)	0 (0%)	0.237
Pneumonia	8 (22%)	4 (16%)	0.583
Pre-Decannulation laboratory data			
White blood cell count (B/L)	16.2 \pm 6.1	20 \pm 8.9	0.096
Platelet count (B/L)	124 \pm 63	130 \pm 61	0.735
Creatinine (mg/dl)	1.2 \pm 0.5	1.2 \pm 0.9	1.000
Bilirubin (mg/dl)	2.6 \pm 3.2	1.7 \pm 1.2	0.125
Aspartate aminotransferase (IU/L)	68 \pm 41	72 \pm 89	0.834
Alanine aminotransferase (IU/L)	71 \pm 71	72 \pm 62	0.953
Lactate (mmol/L)	1.5 \pm 0.5	1.8 \pm 1.8	0.439
Length of ECMO (days)	10 \pm 5.1	8.8 \pm 5.3	0.378
Outcomes			
30-day survival	32 (86%)	19 (76%)	0.289
SIRS Phenomenon			
Fever	35 (95%)	17 (68%)	0.005
Leukocytosis	27 (73%)	4 (16%)	0.000
Escalation of vasopressors	30 (81%)	11 (44%)	0.003
Infection	22 (59%)	10 (40%)	0.133


Table 2: Demographics of patients for Group I (Infection group) and Group TS (True SIRS group). Data are expressed as number (%) or mean \pm standard deviation.

	Group I N=22	Group TS N=15	p-value
Pre-ECMO Demographics			
Age (years)	51 \pm 14	45 \pm 13	0.222
Male gender	18 (82%)	11 (73%)	0.538
Cardiac ECMO	15 (68%)	9 (60%)	0.609
Respiratory ECMO	7 (32%)	6 (40%)	0.609
E-CPR	4 (18%)	1 (6.7%)	0.314
Clinical risk factors			
Coronary artery disease	12 (55%)	4 (27%)	0.093
Post-cardiotomy failure	2 (9.1%)	3 (20%)	0.341
Acute respiratory distress syndrome	6 (27%)	4 (27%)	0.968
Pre-ECMO laboratory data			
White blood cell count (B/L)	14.5 \pm 8	11.1 \pm 4.3	0.104
HCO ₃ (mmol/L)	23 \pm 6	19 \pm 5	0.038
Creatinine (mg/dl)	1.6 \pm 0.8	1.4 \pm 1.0	0.522
Bilirubin (mg/dl)	1.5 \pm 1.6	1.4 \pm 1.7	0.866
Aspartate aminotransferase (IU/L)	134 \pm 196	189 \pm 376	0.615
Alanine aminotransferase (IU/L)	67 \pm 71	123 \pm 269	0.440
Lactate (mmol/L)	4.6 \pm 5.2	5.0 \pm 3.7	0.795
Pre-ECMO Scores			
SAPS II	55 \pm 15	52 \pm 15	0.558
APACHE II	28 \pm 7	29 \pm 10	0.752
MELD	17 \pm 7	14 \pm 8	0.271
Complication during ECMO			
Stroke	2 (9.1%)	0 (0%)	0.230
Pneumonia	3 (14%)	2 (13%)	0.979
Pre-Decannulation laboratory data			
White blood cell count (B/L)	16.6 \pm 5.8	15.5 \pm 6.7	0.608
Platelet count (B/L)	128 \pm 64	120 \pm 63	0.695
Creatinine (mg/dl)	1.3 \pm 0.5	1.1 \pm 0.6	0.295
Bilirubin (mg/dl)	2.5 \pm 3.5	2.6 \pm 2.8	0.924
Aspartate aminotransferase (IU/L)	60 \pm 34	81 \pm 48	0.153
Alanine aminotransferase (IU/L)	57 \pm 50	93 \pm 91	0.172
Lactate (mmol/L)	1.5 \pm 0.6	1.5 \pm 0.4	1.000
Length of ECMO (days)	9.8 \pm 4.7	10.7 \pm 5.8	0.621
Outcomes			
30-day survival	17 (77%)	15 (100%)	0.047

Table 3: Post-decannulation data. Data are expressed as number (%) or mean \pm standard deviation.

	Group I n=22	Group TS n=15	p-value
Incidence of fever	22 (100%)	13 (87%)	0.078
First day of fever (days from decannulation)	1.3 \pm 2.3	0.7 \pm 0.9	0.283
Duration of fever (days)	7.6 \pm 4.9	6.7 \pm 6.0	0.650
Incidence of leukocytosis (%)	16 (73%)	11 (73%)	0.968
First day of leukocytosis (days from decannulation)	1.3 \pm 1.1	1.3 \pm 1.1	1.000
Peak of white blood cell count (B/L)	30.1 \pm 13.3	21.3 \pm 7.7	0.040
Peak of white blood cell count above 30k (B/L)	7 (46%)	3 (14%)	0.026
Duration of leukocytosis (days)	7.3 \pm 4.5	6.0 \pm 4.2	0.450
Escalation of vasopressors (%)	9 (41%)	7 (47%)	0.729
Duration of escalation of vasopressors (days)	5.9 \pm 3.0	4.4 \pm 2.6	0.303
Usage of antibiotics beyond prophylaxis (%)	15 (68%)	8 (53%)	0.531
Duration of antibiotics beyond prophylaxis (days)	8.7 \pm 6.1	6.5 \pm 4.9	0.366

Figure 1: Division of patient groups.



References

1. Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. *J Am Coll Cardiol.* 2014 ;63:2769-78. doi: 10.1016/j.jacc.2014.03.046.
2. Wong JK, Siow VS, Hirose H, Karbowski P, Miessau J, Baram M, DeCaro M, Pitcher HT, Cavarocchi NC. End organ recovery and survival with the QuadroxD oxygenator in adults on extracorporeal membrane oxygenation. *World J Cardiovasc Surg* 2012;2:73-80. doi: 10.4236/wjcs.2012.24015,
3. He C, Yang S, Yu W, Chen Q, Shen J, Hu Y, Shi J, Wu X, Li J, Li N. Effects of continuous renal replacement therapy on intestinal mucosal barrier function during extracorporeal membrane oxygenation in a porcine model. *J Cardiothorac Surg* 2014 Apr 23;9:72. doi: 10.1186/1749-8090-9-72.
4. Haneke F, Schildhauer TA, Schlebes AD, Strauch JT, Swol J. Infections and Extracorporeal Membrane Oxygenation: Incidence, Therapy, and Outcome. *ASAIO J.* 2016;62:80-6. doi: 10.1097/MAT.0000000000000308.
4. Lamb K M, Hirose H, Cavarocchi NC. Preparation and technical considerations for percutaneous cannulation for veno-arterial extracorporeal membrane oxygenation. *J Cardiothorac Surg.* 2013;28:190-2. doi: 10.1111/jocs.12058.
5. Shaheen A, Tanaka D, Cavarocchi NC, Hirose H. Venovenous extracorporeal membrane oxygenation (VV ECMO) indications, preprocedural considerations, and technique. *J Card Surg* 2016; 31:248-252. doi: 10.1111/jocs.12690.
6. Aubron C, Cheng AC, Pilcher D, Leong T, Magrin G, Cooper DJ, Scheinkestel C, Pellegrino V. Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: A 5-year cohort study. *Crit Care.* 2013;17:R73. doi: 10.1186/cc12681.
7. Tanaka D, Pitcher HT, Cavarocchi NC, Hirose H. Can procalcitonin differentiate infection from systemic inflammatory reaction in patients on extracorporeal membrane oxygenation? *J Heart Lung Transplant* 2014;33 (11): 1186-1188. doi: 10.1016/j.healun.2014.08.015.